BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25891208)

  • 1. Conditionally replicating oncolytic adenoviral vector expressing arresten and tumor necrosis factor-related apoptosis-inducing ligand experimentally suppresses lung carcinoma progression.
    Li S; Qi Z; Li H; Hu J; Wang D; Wang X; Feng Z
    Mol Med Rep; 2015 Aug; 12(2):2068-74. PubMed ID: 25891208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapy.
    Li X; Mao Q; Wang D; Zhang W; Xia H
    Hum Gene Ther; 2012 Jun; 23(6):589-96. PubMed ID: 22136065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.
    Shim SH; Lee CT; Hun Hah J; Lee JJ; Park SW; Heo DS; Sung MW
    Cancer Sci; 2010 Feb; 101(2):482-7. PubMed ID: 19922505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.
    Yang Y; Xu H; Huang W; Ding M; Xiao J; Yang D; Li H; Liu XY; Chu L
    J Cell Mol Med; 2015 May; 19(5):915-23. PubMed ID: 25683371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
    Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
    Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapy.
    Chai L; Liu S; Mao Q; Wang D; Li X; Zheng X; Xia H
    Cancer Gene Ther; 2012 Apr; 19(4):247-54. PubMed ID: 22193628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
    Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
    Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
    Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
    Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
    Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo.
    Zhang H; Sui A; Wang Z; Liu S; Yao R
    Int J Mol Med; 2012 Aug; 30(2):358-64. PubMed ID: 22614533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene.
    Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY
    Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.
    Jin J; Liu H; Yang C; Li G; Liu X; Qian Q; Qian W
    Mol Cancer Ther; 2009 May; 8(5):1387-97. PubMed ID: 19417152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis.
    Hu J; Wang H; Gu J; Liu X; Zhou X
    Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1018-1027. PubMed ID: 30137199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.
    Zhu ZB; Rivera AA; Makhija SK; Lu B; Wang M; Izumi M; Cerfolio RJ; Stoff-Khalili MA; Zhou F; Takayama K; Siegal GP; Curiel DT
    Lung Cancer; 2007 Feb; 55(2):145-56. PubMed ID: 17113184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditionally replicating adenovirus combined with gene-targeted radiotherapy induces apoptosis via TRAIL death receptors in MDA-MB-231 cells.
    Wu JH; Wang HF; Wang ZC; Xu K; Qi YL; Li JH; Gong SL; Liu Y; Liu Y
    Mol Med Rep; 2013 Jul; 8(1):299-305. PubMed ID: 23708314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.
    Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Curiel DT
    J Ovarian Res; 2016 Jun; 9(1):38. PubMed ID: 27349517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
    Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
    Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.